Catalysts for $GSK
11 tracked
Oct 28, 2026
earnings
GSK plc earnings
GSK plc
→
Jul 29, 2026
earnings
GSK plc earnings
GSK plc
→
Jul 28, 2026
earnings
GSK plc earnings
GSK plc
→
Apr 29, 2026
earnings
GSK plc earnings
GSK plc
→
Apr 28, 2026
phase 1 completion
GSK plc — bepirovirsen sodium (Phase I Trial Completion)
bepirovirsen sodium
→
Apr 28, 2026
drug expiry
GSK plc — cabotegravir sodium (Drug Expiry (US))
cabotegravir sodium
→
Apr 28, 2026
patent expiry
GSK plc — cabotegravir sodium (Constraining Patent Expiry (US))
cabotegravir sodium
→
Apr 28, 2026
patent expiry
GSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))
(abacavir sulfate + dolutegravir sodium + lamivudine)
→
Apr 28, 2026
patent expiry
GSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))
dolutegravir sodium
→
Apr 25, 2026
phase 2 initiation
GSK plc — dostarlimab (Phase II Trial Initiation)
dostarlimab
→
Jul 30, 2025
recall
Mckesson Medical-Surgical Inc. Corporate Office recall (Cls II)
GSK plc
→